Lead Product(s): Temelimab
Therapeutic Area: Neurology
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Bryan, Garnier & Co
Deal Size: $19.3 million Upfront Cash: Undisclosed
Deal Type: Investment January 31, 2020
Successfully completing this private placement provides GeNeuro the means to complete the planned study of temelimab in multiple sclerosis patients with disability progression without relapses.